Name: Latest research reports of Ipca Laboratories Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: Motilal Oswal

Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Mid-range Performer

1943.2000 16.20 (0.84%)

NSE Oct 01, 2026 15:31 PM

Near 52W High of ₹2038.00

Volume: 324.0K

Ipca Laboratories Ltd.

13 Nov 2025

1943.20

0.84%

Beat on estimates; DF/API drive earnings

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Ipca Laboratories (IPCA) delivered slightly better-than-expected revenue in 2QFY26, while EBITDA/PAT beat our estimates by 18%/22%.

Ipca Laboratories has gained 47.99% in the last 1 Year